Gilead Sciences acquired global rights to an oral oncology candidate from China‑based Genhouse Bio for $80 million upfront, expanding Gilead’s small‑molecule oncology footprint. The deal follows Genhouse’s Hong Kong IPO filing and gives Gilead development and commercialization control over the asset outside limited retained rights. The acquisition underscores continued Western biopharma interest in China‑origin clinical-stage assets and highlights dealmaking as an efficient route to bolster oncology pipelines amid tighter internal R&D focus at some large firms.